CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
disruption in lymphocytes was only approximately 5%, which indicates the need for further research into this approach. (Funded by the Beijing Municipal Science and Technology Commission and others; ClinicalTrials.gov number, NCT03164135.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Subsequent experiments showed that p53 inactivation can be controlled or avoided through protocol optimization 47,107 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [107]
Citations
Cites
1 retracted
CCR5-∆32 is deleterious in the homozygous state in humans
Wei, X., & Nielsen, R. (2019) · Nature Medicine · doi:10.1038/s41591-019-0459-6 · Cited by 75
RetractedIdentification of a major co-receptor for primary isolates of HIV-1
Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M., Marzio, P. D., Marmon, S., Sutton, R. E., Hill, C. M., et al. (1996) · Nature · doi:10.1038/381661a0 · Cited by 3,641
Self-citationSamson, M., Libert, F., Doranz, B. J., Rucker, J., Liesnard, C., Farber, C.-M., Saragosti, S., Lapouméroulie, C., Cognaux, J., Forceille, C., et al. (1996) · Nature · doi:10.1038/382722a0 · Cited by 2,886
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867
Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation
Hütter, G., Nowak, D., Mossner, M., Ganepola, S., Müßig, A., Allers, K., Schneider, T., Hofmann, J., Kücherer, C., Blau, O., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0802905 · Cited by 1,837
Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV
Tebas, P., Stein, D., Tang, W. W., Frank, I., Wang, S. Q., Lee, G., Spratt, S. K., Surosky, R. T., Giedlin, M. A., Nichol, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300662 · Cited by 1,357
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes
Komor, A. C., Badran, A. H., & Liu, D. R. (2017) · Cell · doi:10.1016/j.cell.2016.10.044 · Cited by 1,013
Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency
Aiuti, A., Cattaneo, F., Galimberti, S., Benninghoff, U., Cassani, B., Callegaro, L., Scaramuzza, S., Andolfi, G., Mirolo, M., Brigida, I., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805817 · Cited by 1,007
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases
Perez, E. E., Wang, J., Miller, J. C., Jouvenot, Y., Kim, K. A., Liu, O., Wang, N., Lee, G., Bartsevich, V. V., Lee, Y.-L., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1410 · Cited by 999
Self-citationCRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., et al. (2016) · Nature · doi:10.1038/nature20134 · Cited by 864
Cited by
Items 301–400 of 468
Canarutto, D., Fiumara, M., Venkatesan, V., Gaddoni, C., Shiroshita, K., Varesi, A., Albano, L., Pelosi, G., Silva, A., Firrito, C., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03142-z · Cited by 6
Patro, S. C., Niyongabo, A., Maldarelli, F. M., & Kearney, M. F. (2021) · Viruses · doi:10.3390/v13122475 · Cited by 5
Mudde, A. C. A., Kuo, C. Y., Kohn, D. B., & Booth, C. (2024) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2024.01.019 · Cited by 5
“11 Further research is aimed at improving safety and ef fi cacy of autologous HSC-based gene therapy for HIV infection.”
Baqar, Z., Islam, S. I., Das, G., Mahfuj, S., & Ahammad, F. (2024) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2024.101462 · Cited by 6
Gaining momentum: stem cell therapies for HIV cure
Buck, A. M., LaFranchi, B. H., & Henrich, T. J. (2024) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000859 · Cited by 5
Samson, C., du Rand, A., Hunt, J., Whitford, W., Jacobsen, J. C., & Sheppard, H. M. (2024) · Journal of the Royal Society of New Zealand · doi:10.1080/03036758.2024.2347968 · Cited by 5
Калиниченко, С. В., RAMADAN, L., Kruglova, N. A., Balagurov, K., Игоревна, Л. М., Mazurov, D. V., & Shepelev, M. V. (2024) · Biology · doi:10.3390/biology13090675 · Cited by 5
Ameratunga, R., Leung, E. Y., Woon, S., Lea, E., Allan, C. L. M., Chan, L., Longhurst, H. J., Steele, R., Snell, R. G., & Lehnert, K. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109854 · Cited by 8
Development and assessment of cutting-edge biotechnologies
Hu, X., Xu, B., Chen, M., Li, K., Xiao, Y., Liang, S., Zhang, C., Ma, H., & Song, H. (2024) · Journal of Biosafety and Biosecurity · doi:10.1016/j.jobb.2024.03.001 · Cited by 6
Hematopoietic stem cell transplantation and cellular therapy in persons living with HIV
Rubinstein, P. G., Galvez, C., & Ambinder, R. F. (2024) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000001022 · Cited by 5
“2) [48 55]. modified stem cells and autoSCT (NCT02797470) [50,52].”
HLA-mismatched allogeneic adoptive immune therapy in severely immunosuppressed AIDS patients
Xu, R., Zhang, J., Tu, B., Xu, Z., Huang, H.-H., Huang, L., Jiao, Y., Yang, T., Zhang, C., Qin, E., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00550-2 · Cited by 5
Third patient free of HIV after receiving virus-resistant cells
Reardon, S. (2023) · Nature · doi:10.1038/d41586-023-00479-2 · Cited by 6
Wang, Z., Lai, L., Ran, S., Li, Y., Zhao, J., Wu, J., Guo, C., Cui, J., & Xia, J. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07383-5 · Cited by 6
“Engineered CD4 + stem-like memory T cell populations demonstrate both long-term persistence and the capacity to generate antiviral effectors, enabling functional control of HIV in the absence of continued pharmacotherapy [187].”
Du, J., Luo, Z., Xie, D., Chen, Y., Yang, M., Li, Q., Wang, L., Han, L., Zhang, Y., Li, H., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01765-w · Cited by 6
Self-citationMahmood, M., Taufiq, I., Mazhar, S., Hafeez, F., Malik, K. A., & Afzal, S. (2024) · Personalized Medicine · doi:10.1080/17410541.2024.2341610 · Cited by 6
Ex vivo functional whole organ in biomedical research: a review
Chelladurai, K. S., Christyraj, J. D. S., Rajagopalan, K., Vadivelu, K., Chandrasekar, M., Das, P., Kalishwaralal, K., Balamurugan, N., Subramanian, V., & Christyraj, J. R. S. S. (2024) · Journal of Artificial Organs · doi:10.1007/s10047-024-01478-4 · Cited by 5
“In addition, it has demonstrated promising outcomes in various genetic diseases such as progeria during the preclinical stage [32] and in the management of HIV-AIDS [73].”
In pursuit of an HIV cure: from stem cell transplants to gene therapies
Clees, J., Basic, M., Cruz, P. E., Ramirez, S. H., & Andrews, A. M. (2025) · Frontiers in Genome Editing · doi:10.3389/fgeed.2025.1634193 · Cited by 5
Li, M., Morse, B. A., & Kassim, S. H. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2101361 · Cited by 4
“Donor screening should minimally include a basic testing panel of infectious disease markers 30 days prior to collection (e.g. hepatitis, HIV, CMV, and others).”
BackgroundRecent developments in CCR5 regulation for HIV cure
Garg, K., Khan, A. R., & Taneja, P. (2021) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2021.01.004 · Cited by 4
Transient CD4-cell-depletion therapy for HIV/AIDS cure
Wei, M., & Shao, Y. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001654 · Cited by 4
“This disadvantage results in the failure of the HIV/AIDS cure.([6])”
BackgroundYang, T., Xie, Z., Xu, Z., Tu, B., Lu, H., Huang, H., Huang, L., Zhang, C., Gao, L., Jin, L., et al. (2024) · Emerging Microbes & Infections · doi:10.1080/22221751.2024.2364744 · Cited by 4
“…recently, research efforts have been directed toward exploring the applicability of genetically modified CD4+ T and hematopoietic stem cells (HSCs) derived from either autologous sources or HLA-matched donors in reinstat-ing the immunological response in individuals infected with HIV-1 [18, 19].”
BackgroundSelf-citationApplication of synthetic biology in bladder cancer
Ding, M., Lin, J., Qin, C., Wei, P., Tian, J., Lin, T., & Xu, T. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002344 · Cited by 3
“To date, clinical trials based on CRISPR/Cas9 gene editing have been carried out in transthyretin amyloidosis,([40]) sickle cell disease and b-thalassemia,([41]) HIV and acute lymphocytic leukemia.([42]) The primary results are encouraging.”
BackgroundExcision of HIV-1 Provirus in Human Primary Cells with Nanocapsuled TALEN Proteins
Zhao, M., Wen, J., Chen, I. S. Y., Liu, J., & Lu, Y. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.4c01544 · Cited by 4
From natural defenders to therapeutic warriors: NK cells in HIV immunotherapy
Laeremans, T., Janssens, A., & Aerts, J. L. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2460965 · Cited by 3
HIV reservoirs in lymphomagenesis: hidden driver in the era of viral suppression?
Li, Y., Xiao, Q., Yu, F., & Zhang, F. (2025) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00104-25 · Cited by 4
“…palindromic repeats) technology have introduced new possibilities for modifying donor stem cells to carry the CCR5Δ32 mutation, as demonstrated in an attempt to cure HIV in a patient with acute lymphocytic leukemia using CRISPR-mediated CCR5-ablated hematopoietic stem and progenitor cells (186).”
Miniaturized CRISPR: Ultra Compact Systems for In Vivo Delivery and Portable Diagnostics
Saxena, S., Saxena, S., & Gupta, D. (2026) · Annals of Biomedical Engineering · doi:10.1007/s10439-026-04046-4 · Cited by 4
“In a similar vein, the case of a patient with acute lymphocytic leukemia and HIV who received autologous hematopoietic stem cells which were edited demonstrated successful engraftment, but in an unenthusiastic manner [51].”
In vitro and in vivo base editing of CCR5 in hematopoietic stem cells confers HIV-1 resistance
Anderson, A. K., Georgakopoulou, A., Kuhlmann, A.-S., Wang, H., Riker, A. O., Karuppusamy, K. V., Radtke, S., Bui, J. K., Kiem, H., Lieber, A., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.03.018 · Cited by 4
Self-citationApplications of genome editing technologies in the treatment of human diseases
Alshorman, J., Mehran, M. J., Tembo, K. M., Mostafavi, N., Bolideei, M., & Wang, Y. L. (2026) · Gene Therapy · doi:10.1038/s41434-026-00627-z · Cited by 4
Lin, W., Chen, Y., Lin, C., Yang, Y.-P., Wang, M., Hung, K.-F., Huang, P., Lee, Y., & Chiou, S. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000358 · Cited by 3
Zeng, X. X., Zeng, J., & Zhu, B. (2021) · Reviews in the Neurosciences · doi:10.1515/revneuro-2021-0068 · Cited by 4
Recent developments in genome design and assembly tools
Barreiro, C., & García‐Estrada, C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824469-2.00012-9 · Cited by 4
Widjaya, M. A., Ju, J.-C., & Lee, S. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10345-9 · Cited by 3
“Furthermore, in vivo is a critical point to make sure the drug works efficiently before we continue the drug testing in humans [19].”
BackgroundOutlook on the Security and Potential Improvements of CRISPR–Cas9
Zha, M.-J., Cai, C., & He, P. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00708-z · Cited by 3
“CAR-T, as the first gene editing technology applied to the treatment of human diseases [11], has many successful treatment cases, and its clinical application is safe and feasible [12].”
BackgroundCord blood grafts for patients with HIV?
Scaradavou, A. (2023) · Cell · doi:10.1016/j.cell.2023.01.024 · Cited by 3
Au, T. Y., Arudkumar, J., Assavarittirong, C., & Benjamin, S. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01129-7 · Cited by 3
“A similar approach to that discussed could be potentially utilized to achieve complete remission of HIV in HIV-infected patients with hematological malignancies [31].”
InfluentialChen, Y., Song, Y., Zhu, X., Dong, C., & Chen, M.-S. (2023) · Journal of macromolecular science. Part C, Reviews in macromolecular chemistry and physics/Journal of macromolecular science. Reviews in macromolecular chemistry and physics · doi:10.1080/15583724.2023.2281462 · Cited by 3
CRISPR-Cas9 for the Treatment of Transthyretin Cardiac Amyloidosis
Panichella, G., & Aimo, A. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128267417231127070901 · Cited by 3
Current progress in CRISPR–Cas systems for cancer
Fatima, H., Raja, H. A., Amir, R., Gul, A., Babar, M. M., & Rajadas, J. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.07.007 · Cited by 4
Xu, P., Yuan, D., Moog, C., & Su, B. (2025) · Science China Life Sciences · doi:10.1007/s11427-024-2840-4 · Cited by 3
“Advances in gene-editing technologies, such as CRISPR (Xu et al., 2019) and immunotherapies, as well as potential curative approaches, including hematopoietic stem cell transplantation and immune enhancement therapies, can offer hope for functional cures.”
Self-citationScientists use gene-edited stem cells to treat HIV — with mixed success
Lambert, J. (2019) · Nature · doi:10.1038/d41586-019-02719-w · Cited by 3
Beschorner, N., Künzle, P., Voges, M., Hauber, I., Indenbirken, D., Nakel, J., Virdi, S., Bradtke, P., Lory, N. C., Rothe, M., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0298542 · Cited by 3
“…mentioned above, inactivation of the ccr5 gene in PLWH-derived cells by engineered designer nucleases, such as zinc-finger nucleases (ZFN), transcription activator-like effector nucleases (TALEN), or the CRISPR/Cas system, currently represents a highly active field of HIV cure research [31–35].”
BackgroundGenome-wide CRISPR/Cas9 screen reveals JunB downmodulation of HIV co-receptor CXCR4
Schulze, W. J., Gregory, D. A., Johnson, M. C., & Lange, M. J. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1342444 · Cited by 2
Opportunities and challenges in achieving a functional cure for HIV
Zhang, W., Zhou, M., Chen, J., He, Y., & Li, L. (2025) · Infectious Diseases & Immunity · doi:10.1097/id9.0000000000000175 · Cited by 2
“[65] Recently, a case report showed that a male achieved HIV remission over 32 months without cART after allogeneic HSCT with wild-type CCR5 donor cells, although the CD4 + T cells remained permissive to HIV infection.”
Shamsi, A., Alrouji, M., AlOmeir, O., Tasqeruddin, S., Khuzin, D., & Zuberi, A. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1681891 · Cited by 5
“These results include the application of CRISPR/Cas9-linked therapies for diseases like β -thalassemia, sickle cell disease (SCD), acquired immunodeficiency syndrome (AIDS), and various malignancies (Cyranoski, 2016; Frangoul et al., 2021; Xu et al., 2019).”
Guo, X., Lin, M., Xu, S., Liu, B., Zhang, R., Liu, S., & Pan, Y. (2025) · Bone and Joint Research · doi:10.1302/2046-3758.1410.bjr-2024-0477.r1 · Cited by 3
CRISPR Applications in HIV Management – Prevention, Diagnosis, Monitoring and Treatment
Marques, B. S., Vitorino, C., & Ventura, F. V. (2026) · Current HIV/AIDS Reports · doi:10.1007/s11904-025-00769-6 · Cited by 2
“Furthermore, while common transplant-related adverse effects were observed, no toxicity from CCR5 gene editing was reported [ 77 ].”
Cho, E., Lee, J., Kim, J., Choi, J., Kang, M., & Song, J. (2026) · Journal of Biological Engineering · doi:10.1186/s13036-026-00673-6 · Cited by 3
“C chemokine receptor type 5 (CCR5) editing in hematopoietic stem and progenitor cells (HSPCs) led to stable engraftment in HIV-1 treatment [31], while BCL11A knockout in CD34 + HSPCs induced fetal hemoglobin expression in sickle cell disease (SCD) and transfusion-dependent β-thalassemia (TDT) [32].”
Expanding the Microbial Genomic Landscape and Biotechnological Applications of CRISPR-Cas Systems
Singh, S., Tiwari, H., Singh, M., Gautam, V., Gautam, A., & Gautam, H. K. (2026) · Biology · doi:10.3390/biology15100748 · Cited by 2
Ciganek, I., Delehedde, C., Galy, A. H. M., Cogné, M., Rameix, N., Bordeianu, C., & Pichon, C. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103334 · Cited by 3
“…expanded to immune and progenitor cells for cancer and human immunodeficiency virus type 1 (HIV-1) infection treatments, marking the beginning of a rapid expansion in gene editing-based immunotherapies and further solidifying the convergence of these two fields in clinical development [29,30].”
The future of pediatric gene therapy: CRISPR-Cas9, AI, and personalized medicine
Pan, Y., Ding, J., Wang, W., Xu, D., Fan, J., & Zhang, W. (2026) · Pediatric Research · doi:10.1038/s41390-026-05270-3 · Cited by 2
Hamilton, S. R. (2020) · Cell · doi:10.1016/j.cell.2020.03.012 · Cited by 2
Gene Therapy for Human Diseases: Recent Achievements and Near-Term Development Prospects
Айтбаев, К. А., Murkamilov, I. T., Абдилалимовна, М. Ж., & Yusupov, F. A. (2022) · The Russian Archives of Internal Medicine · doi:10.20514/2226-6704-2022-12-5-363-369 · Cited by 2
Precise insertions of large DNA fragments for cell and gene therapy
Li, G., Zhang, Q., Liang, T., & Huang, X. (2023) · 中国科学通报:英文版 · doi:10.1016/j.scib.2023.04.013 · Cited by 2
A Primer on Gene Editing: What Does It Mean for Pathologists?
Cushman‐Vokoun, A. M., Schmidt, R. J., Hiemenz, M., Fung, M. K. Y., Zhang, B. M., Bradshaw, G., Gandhi, M. J., Yao, J., Yohe, S. L., Beckman, A. K., et al. (2023) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2022-0410-cp · Cited by 2
Self-citationGene Editing in Hematopoietic Stem Cells
Liao, J., & Wu, Y. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-99-7471-9_11 · Cited by 4
Genetic modification of mice using CRISPR-Cas9: Best practices and practical concepts explained
Hosur, V., Low, B. E., & Wiles, M. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-817218-6.00018-8 · Cited by 3
Đinh, L., Blackard, J. T., Robertson, J., Atreya, A., Horner, S., Brown, J. L., Gómez, L. A., Beegle, S., Mahon, L., Eades, W. C., et al. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.125157 · Cited by 2
Pan, M., Cao, W., Zhai, J., Zheng, C., Xu, Y., & Zhang, P. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143134 · Cited by 2
Gene Editing Expands the Donor Pool for CCR5-Negative Stem Cell Transplants
Cannon, P. M. (2019) · Cell stem cell · doi:10.1016/j.stem.2019.11.006 · Cited by 2
Koh, E.-Y., You, J.-E., Jung, S.-H., & Kim, P. (2019) · Korean Journal of Clinical Laboratory Science · doi:10.15324/kjcls.2019.51.4.475 · Cited by 2
“지 못하고 분화하거나 암종으로 변이될 수 있다는 보고가 있다 [12, 28-30].”
What’s Hot in HIV in 2019—A Basic and Translational Science Summary for Clinicians From IDWeek 2019
Titanji, B. K., & Kelley, C. F. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa053 · Cited by 2
“Xu and colleagues demonstrated promising clinical feasibility for another CRISPR-Cas9 gene-editing approach to HIV cure in a single patient [16].”
BackgroundTHE GORDON WILSON LECTURE: THE ETHICS OF HUMAN GENOME EDITING.
Coller, B. S. (2020) · PubMed Central · Cited by 4
Moving Toward a Functional Cure for HIV-1
Kang, W., & Sun, Y. (2021) · Infectious Diseases & Immunity · doi:10.1097/id9.0000000000000025 · Cited by 2
“Nevertheless, despite the complete remission of acute leukemia, only about 5% of the lymphocytes remained CCR5-null, which was not enough to resist HIV reinfection.([16]) Further research into this approach is necessary to improve the efficiency ofCCR5 gene knockout using the CRISPR/Cas system.”
Role of CRISPR Technology in Gene Editing of Emerging and Re-emerging Vector Borne Disease
Mahto, K. K., Prasad, P., Kumar, M., Dubey, H., & Ranjan, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.104100 · Cited by 2
Advances in HIV Eradication Strategies
Mei, Q., Wang, W., Wu, J., & Gao, Y. (2022) · Infectious Microbes & Diseases · doi:10.1097/im9.0000000000000088 · Cited by 2
“this method has the risk of allogeneic transplant rejection and other side effects and has not been replicable in HIV-infected patients who do not suffer from hematological diseases.(9) The third person in the world cured of HIV now has undetectable”
MethodZeebroeck, S. V. (2022) · Global Bioethics Enquiry Journal · doi:10.38020/gbe.10.2.2022.96-100 · Cited by 1
CRISPR/Cas patents and health-related publications in South America
Frâncio, L., de Freitas, M. V., & Matte, Ú. D. S. (2023) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765202320220629 · Cited by 1
“Lymphoblastic leukemia remission was observed 19 months (2023) 95(2) e20220629 9 | 13 after transplant when cells with the modified CCR5 gene persisted (Xu et al. 2019).”
BackgroundGene therapy to cure HIV infection
Goguen, R. P., Chen, M. J., Dunkley, O. R. S., Gatignol, A., & Scarborough, R. J. (2023) · Virologie · doi:10.1684/vir.2023.1021 · Cited by 3
CRISPR/Cas-based diagnosis and treatment of infectious diseases
Wang, X., Lǐ, Y., & Huang, X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-818619-0.00077-0 · Cited by 2
Self-citationWang, W., Zhang, L., Li, H., & Teng, Z. (2025) · Mathematical Methods in the Applied Sciences · doi:10.1002/mma.70165 · Cited by 1
Salwe, S., & Shete, A. (2026) · Current HIV/AIDS Reports · doi:10.1007/s11904-026-00778-z · Cited by 1
Precision gene editing: From proof-of-concept to curative therapies
Cui, T., Li, B., Cai, B., Wang, H., & Li, W. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2026.06.004 · Cited by 1
CRISPR-HAWK: haplotype- and variant-aware guide design toolkit for CRISPR-Cas
Kumbara, A., Tognon, M., Carone, G., Fontanesi, A., Bombieri, N., Giugno, R., & Pinello, L. (2026) · Bioinformatics · doi:10.1093/bioinformatics/btag708 · Cited by 2
“5A) including TRBC1/TRBC2 (Stadtmauer et al. 2020), HBB (DeWitt et al. 2016, Xu et al. 2019b), HBG1/ HBG2 (De Dreuzy et al. 2019, Métais et al. 2019) and CCR5 (Xu et al. 2017, 2019a) genes.”
Cellular and Immune Therapy for Treating HIV-1 Infection
Xia, L., Zhou, Q., Zou, R., Li, W., & Zou, W. (2021) · Aids Reviews · doi:10.24875/aidsrev.20000110 · Cited by 1
Application of genome editing technology in human gene therapy
Mitani, K. (2020) · Translational and Regulatory Sciences · doi:10.33611/trs.2020-007 · Cited by 2
“Although it has been regarded as a highly promising treatment, the results reported in the literature thus far, show that the therapeutic effects have not been so remarkable [7, 8].”
ResultNóbrega, C., Mendonça, L. S., & Matos, C. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-41333-0_8 · Cited by 1
Management of autoinflammatory syndromes and periodic fevers
Peet, C. J., & Lachmann, H. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-95061-9.00049-7 · Cited by 2
Applications of CRISPR-Cas9 Technology to Treat CCR5 Tropic HIV-1
Tandon, A., & Feist, W. N. (2022) · Journal of Student Research · doi:10.47611/jsrhs.v11i4.3464 · Cited by 1
Cheng, J., Zhang, B., Cai, W., Zhao, S., Deng, X., Wang, B., Zhu, X., Lv, Y., Zhu, W., Zhang, X., et al. (2024) · Fundamental Research · doi:10.1016/j.fmre.2024.03.003 · Cited by 1
“With the advancement of genetic engineering technologies, human PSCs could be engineered for lineage labeling and tracing [12] , correction of mutated gene loci [13 , 14] , and control of cell function and safety after transplantation [15–17] .”
Self-citationCRISPR-cas technology and use in antiviral development
Şeflek, Z. Y., & Hasöksüz, M. (2024) · Journal of Istanbul Veterinary Sciences · doi:10.30704/http-www-jivs-net.1497783 · Cited by 1
Bazazzadegan, N., Hasanzad, M., & Abedini, S. S. (2024) · Springer eBooks · doi:10.1007/978-981-97-4974-4_9 · Cited by 1
Mintaev, R. R., Glazkova, D. V., Taran, J. А., Bogoslovskaya, E. V., & Shipulin, G. A. (2025) · Molecular Biology · doi:10.1134/s0026893324700833 · Cited by 1
First CRISPR editing trial results assuage safety concerns
Reardon, S. (2019) · Nature Medicine · doi:10.1038/d41591-019-00019-4 · Cited by 2
Gao, C., & Chen, J. (2021) · The CRISPR Journal · doi:10.1089/crispr.2021.29129.gao · Cited by 1
Chávez, L., Reddy, N. R., Raymond, K. A., Bouzidi, M. S., Desai, S., Dossani, Z. Y., Sperber, H. S., Theiler, J. P., Korber, B., & Pillai, S. K. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.10.243329 · Cited by 1
Soltaninejad, H., Khoshandam, M., Hamidieh, A. A., & Hosseinkhani, S. (2022) · Authorea · doi:10.22541/au.165268627.74823408/v1 · Cited by 1
New hope for cure of HIV-infected patients
Jiao, Y., Zhang, C., & Wang, F. (2024) · Infectious Diseases & Immunity · doi:10.1097/id9.0000000000000143 · Cited by 1
“[10] Moreover, CCR5-modified autologous CD4 + T cells are being investigated in preclinical and clinical studies as potential components of a cure for HIV infection.”
Pharmacological means of personalized medicine: main global trends.
Ломоносов, А. В., & Samsonov, M. (2020) · Terapevt (General Physician) · doi:10.33920/med-12-2001-04
HIV: Can gene editing provide a cure for HIV?
Sandal, S., Arora, V., Bijarnia‐Mahay, S., Verma, I. C., & Puri, R. D. (2020) · Current Medicine Research and Practice · doi:10.1016/j.cmrp.2020.07.012
Les révolutions technologiques : de la prédiction au ciblage thérapeutique
Hassoun, D., Djukanović, R., Bedel, A., & Vos, J. D. (2020) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(20)30016-1
Stem Cell Transplantation for HIV-Related Lymphoma
Smith, S. E., & Gallicchio, V. S. (2019) · Stem Cell & Regenerative Medicine · doi:10.33425/2639-9512.1038
“Only a small portion of the CD4+ cells, 5%, showed phenotypic characteristics of the CCR5 disruption [40].”
BackgroundInfluentialOltolini, C., Piemontese, S., Ripa, M., Greco, R., Nozza, S., Corti, C., Peccatori, J., Scarpellini, P., Ciceri, F., & Castagna, A. (2020) · Transplant Infectious Disease · doi:10.1111/tid.13551
Wang, L., Huang, J., Yang, S., Huang, S., & Li, N. (2020) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2020-0457 · Cited by 1
Self-citationBioanalytical Challenges and Strategies of Crispr Genome Editors
Hölttä, M., Nitsch, R., & Henderson, N. (2021) · Bioanalysis · doi:10.4155/bio-2020-0215
Generating Isogenic Models of Li-Fraumeni Syndrome and Restoring p53 using CRISPR
Tran, J. (2020) · TSpace (University of Toronto)
CRISPR-Cas, el editor de genes
Alegre, D. M. I., Mazzuoccolo, L. D., & Rinflerch, A. (2021) · Revista del Hospital Italiano de Buenos Aires · doi:10.51987/revhospitalbaires.v41i1.71
HIV—Disease Overview, Targets for Therapy and Open Issues
Stephan, C. (2021) · Methods and principles in medicinal chemistry · doi:10.1002/9783527810697.ch1
Lundstrom, K. H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818731-9.00137-3
Genome‐Editing Applications in Stem Cell Engineering and Regenerative Medicine
Gupta, P., Jaitly, S., Thakur, P., Goswami, S. G., Bhargava, N., & Ramalingam, S. (2022) · Wiley eBooks · doi:10.1002/9781119671404.ch17
Metadata
- Authors
- Xu, L., Wang, J., Liu, Y., Xie, L., Su, B., Mou, D., Wang, L., Liu, T., Wang, X., Zhang, B., Zhao, L., Hu, L., Ning, H., Zhang, Y., Deng, K., Liu, L., Lu, X., Zhang, T., Xu, J., Li, C., Wu, H., Deng, H., & Chen, H.
- Affiliations
- Peking University (CN)
- Capital Medical University (CN)
- Sun Yat-sen University (CN)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-09-26
- Volume
- 381
- Issue
- 13
- Pages
- 1240-1247
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2972390440
- Cited by
- 454
- References
- 27
- Citations by year
- 2026: 34 · 2025: 52 · 2024: 57 · 2023: 45 · 2022: 77 · 2021: 87 · 2020: 89 · 2019: 13
- FWCI
- 21.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Key Research and Development Program of China (2017YFA0103000)
- Beijing Municipal Science and Technology Commission (D171100000517004)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- CRISPR gene editing, hematopoietic stem cells, HIV, acute lymphoblastic leukemia, gene therapy
- MeSH terms
- Gene Editing, Adult, Blood Cell Count, Hematopoietic Stem Cells, Humans, Male, HIV-1, HIV Infections, Hematopoietic Stem Cell Transplantation, CD4 Lymphocyte Count, Viral Load, Receptors, CCR5, Anti-Retroviral Agents, Precursor Cell Lymphoblastic Leukemia-Lymphoma, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.